PSA doubling time, seminal vesicle invasion, and efficacy of salvage radiation therapy

A small study from one hospital in Norway has suggested that PSA doubling times after surgery may predict the value of salvage radiation therapy alone as a second line form of therapy. … READ MORE …

“Advances in prostate cancer 2014″

For those seeking a good, thorough, and relatively quick update on major advances in prostate cancer risk, diagnosis, and management in the past year, there is such an article just published on the Medscape web site. … READ MORE …

Provenge to remain available during Dendreon bankruptcy

According to a media release issued by Dendreon Corp. early this morning, the company will be declaring Chapter 11 bankruptcy but is assuring physicians and patients that sipuleucel-T (Provenge) will continue to remain available during the company’s restructuring. What is a good deal less clear is whether the company will be sold after the restructuring or will continue to operate as a stand-alone entity.

The U.S. FDA wants your input — by December 4 this year

Do you have views on how the U.S. Food and Drug Administration (FDA) should be seeking and obtaining the views of patients during the development process for drugs and medical devices, and on ways to consider patients’ perspectives during regulatory discussions about the evaluation and approval of such products? … READ MORE …

Another Bayer, radium-223 (Xofigo) update

According to information on the Malecare Facebook page, Bayer is hoping to be able to re-start manufacturing of radium-223 at their plant in Norway at some time in November. However, no specific date has been provided for product availability, as yet.

Our cancer care system IS in crisis, and …

… the situation is laid out in some detail in an article by Payne and Dale on the Health Affairs blog site. Additional commentary can be found on the Medscape Oncology site. … READ MORE …

Chimeric antigen receptor T-cell (CART) therapy: current data, future potential

An article in today’s issue of the New England Journal of Medicine reports data from a Phase II trial of CART therapy in the treatment of patients with acute lymphoblastic leukemia or ALL (an aggressive and difficult to treat form of cancer). This is arguably one of the most exciting papers on the treatment of cancer in the past 50+ years. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,182 other followers